Long Timelines and High Costs of Drug Development, and the Risk of Discontinuation and Delays
First written in FY2016. 25 of 26 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
29 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company continues to disclose the long development timelines, high costs and possibility of discontinuation or delay associated with drug development. - FY2025-H1RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded. - FY2024-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before product approval and sales can be recorded in its disclosures on material events relating to its ability to continue as a going concern. - FY2024-Q1RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded. - FY2023RestatedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company continues to disclose the long development timelines, high costs and possibility of discontinuation or delay associated with drug development. - FY2023-Q2RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded in its going-concern disclosures. - FY2022RestatedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company continues to disclose the long development timelines, high costs and possibility of discontinuation or delay associated with drug development. - FY2022-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded in its going-concern disclosures. - FY2022-Q2RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2021RestatedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company continues to disclose the long development timelines, high costs and possibility of discontinuation or delay associated with drug development. - FY2021-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2021-Q2RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2021-Q1RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company reiterates the lengthy period and substantial funding required before approval and product sales can be recorded as a material event relating to its ability to continue as a going concern. - FY2020RestatedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company continues to disclose the long development timelines, high costs and possibility of discontinuation or delay associated with drug development as general business risks. - FY2020-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2020-Q2RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded in its going-concern disclosures. - FY2020-Q1RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded in its going-concern disclosures. - FY2019-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2019-Q2RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before pharmaceutical approval and product sales can be recorded in its going-concern disclosures. - FY2019-Q1RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2018-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2018-Q2RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to highlight the lengthy period and substantial funding required before approval and product sales can be recorded in its going-concern disclosures. - FY2017RestatedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company continues to disclose the long development timelines, high costs and possibility of discontinuation or delay associated with drug development as general business risks. - FY2017-Q3RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company continues to explain the lengthy period and financial burden involved before approval and product sales can be recorded. - FY2017-Q1RestatedAnnual report
「The drug discovery business operated by the company requires substantial funding and a long period of time before it can generate business revenue from sales of products approved as pharmaceuticals.」
The company reiterates the lengthy period and financial burden involved before approval and product sales can be recorded in its going-concern disclosures. - FY2016First statedAnnual report
「The process of developing a drug through to product launch requires a long period of time and substantial expense. The probability of successful development is by no means high, and it is not unusual for development to be discontinued or delayed at any stage.」
The company discloses the possibility of discontinuation or delay at each stage of development as a general business risk.